pharmaphorum
FEBRUARY 9, 2022
In this article, Ben Hargreaves looks into the promise of cancer vaccines and how this treatment modality may offer advantages over existing immunotherapies in the oncology sector. According to a report by IQVIA last year, there were 3,500 oncology-focused therapeutic candidates in the pipeline, which represents a 75% increase on figures seen in 2015.
Outsourcing Pharma
FEBRUARY 7, 2022
The HIV-focused pharma company announced the agency has approved Cabenuva for administration as few as six times a year for adults living with the virus.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharma Marketing Network
FEBRUARY 10, 2022
Experts from top life sciences companies discussed strategies for more effectively engaging oncologists at the Pharma Marketing Network’s 2022 Future Forecast on January 25 th. Here are the top three things to know about engaging oncologists in 2022: 1. Lead with clinical education. It’s no longer enough to build brand awareness, according to the panelists.
Dr. Jamie Hardy: The Lifestyle Pharmacist
FEBRUARY 11, 2022
Magnificent, vibrant, and flavorful are characteristics that come to mind when I think about Puerto Rico. I recently had the pleasure of visiting this Caribbean gem and it’s safe to say that I had a wonderful time. I did a little bit of research while prepping for my trip. I was amazed to learn that the island of Puerto Rico has almost 300 miles of coastline and nearly the same number of beaches.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
pharmaphorum
FEBRUARY 9, 2022
The digitalisation that we all experience daily has affected the way we engage with stakeholders and patients. But how can we make Customer Engagement effective, and how can we leverage technologies like AI and Marketing Automation to their best potential? The key to success lies in implementing a digital health ecosystem , in order to support the shift from an organization-centric model to a customer-centric model by using digital platforms.
Outsourcing Pharma
FEBRUARY 8, 2022
The latest in the Diversity in Oncology series, taking place February 9, will discuss ways academia and community collaboration can narrow representation gaps.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Policy Prescription
FEBRUARY 9, 2022
Mark Cuban’s new online pharmacy venture – the Mark Cuban Cost Plus Drug Company (“Cost Plus Drug”) – will not help overcome the biggest obstacle to drug affordability in America, which is drug company monopolies on patented brand name prescription drugs. When only one company makes a drug and can charge as much as the market will bear, which is the case in the United States, the prices are often outrageous, with several treatments exceeding half a million dollars.
pharmaphorum
FEBRUARY 10, 2022
With staff shortages and digital skill gaps being experienced across the spectrum of healthcare, from CROs and pharma to providers, the people-led sector is facing a personnel challenge that could threaten the potential of digital transformation. The healthcare ecosystem may be the natural beneficiary of recent advances in data collection and analysis, but that’s no use without the staff to develop and implement solutions.
Outsourcing Pharma
FEBRUARY 9, 2022
The companyâs analysis of trials conducted around the world last year shows cancers took four of the top five positions, with COVID-19 in second place.
Pharma Marketing Network
FEBRUARY 10, 2022
Change champions from top life sciences companies discussed how to manage the constant wave of change pharma marketing teams are facing at the Pharma Marketing Network’s 2022 Future Forecast on January 25 th. Here are the top three things to know about preparing your pharma marketing team for change in 2022: 1. Your marketing best practices still apply!
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Med Ed 101
FEBRUARY 9, 2022
If you work in geriatrics to any extent at all, you’re likely familiar with anticholinergic activity. If you’ve learned anything, you know that more is NOT better when it comes to anticholinergic adverse effects. We want to avoid these side effects, but how do we apply this mentality from a practical standpoint? Let me share […]. The post Minimizing Anticholinergic Adverse Effects – Case Study appeared first on Med Ed 101.
pharmaphorum
FEBRUARY 8, 2022
Novo Nordisk’s new obesity therapy Wegovy has been recommended for routine NHS use by UK cost-effectiveness watchdog NICE, but in a narrower group of patients than is covered by its MHRA-approved label. NICE has backed use of the Wegovy (semaglutide) for people with a body mass index (BMI) of 35 kg/m2 or more and at least one weight-related ailment – such as high blood pressure, high cholesterol or diabetes – as part of a weight management programme involving exercise and a reduce-calorie
Outsourcing Pharma
FEBRUARY 10, 2022
In the first of a two-part series, leaders from the CRO discuss how study data has progressed in recent years and how trial teams can keep up effectively.
Pharma Marketing Network
FEBRUARY 10, 2022
Innovative social media marketers from top life sciences companies discussed the secrets to their success at the Pharma Marketing Network’s 2022 Future Forecast on January 25 th. Here are the top three things to know about pharma social media trends in 2022: 1. Don’t be afraid to try new things. Social media trends change all the time, and pharma marketing organizations have to be nimble to make the most of them, according to Lauren Sacks , Director of Omnichannel Marketing at Biohaven Pharmaceu
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Med Ed 101
FEBRUARY 6, 2022
As a pharmacist, it is critical to recognize that infertility is a significant problem. There are a variety of causes and etiologies for female infertility, many of which remain unknown. Almost 13% of women between ages 15-44 seek treatment for infertility each year. There are many infertility medications available today that may be used throughout […].
pharmaphorum
FEBRUARY 11, 2022
Komodo Health’s president and co-founder, Web Sun, tells us about his company’s new partnership with the Chan Zuckerberg Initiative (CZI) to improve early diagnosis and advance research of rare diseases by providing CZI’s Rare as One Network healthcare data and software. Though 7,000 rare diseases exist that affect 400 million people globally, a lack of understanding of these diseases can cause a delay in diagnosis and, in turn, treatment.
Outsourcing Pharma
FEBRUARY 10, 2022
The pharmaceutical company, which uses thin-film freezing to develop inhalable therapies, has completed enrollment in the first phase for its drug candidate.
Pharma Marketing Network
FEBRUARY 10, 2022
Change champions from top life sciences companies discussed how to manage the constant wave of change pharma marketing teams are facing at the Pharma Marketing Network’s 2022 Future Forecast on January 25 th. Here are the top three things to know about preparing your pharma marketing team for change in 2022: 1. Your marketing best practices still apply!
Pharma Times
FEBRUARY 7, 2022
Institute for Cancer Research highlights missed opportunity for NICE to reform its cancer drug assessment processes
pharmaphorum
FEBRUARY 9, 2022
GlaxoSmithKline’s COVID-19 products – antibody drug Xevudy and a vaccine adjuvant – helped drive a 5% increase in 2021 revenues to £34 billion ($46 billion), ahead of what chief executive Emma Walmsley says will be a “landmark year” for the company. Xevudy (sotrovimab), which was developed with Vir Biotech and has seen its use rise after it was shown to be effective against the Omicron strain of SARS-CoV-2, brought in £958 million, £828 million of that in the last quarter of th
Outsourcing Pharma
FEBRUARY 7, 2022
An expert from the CRO discusses the role real-world data plays in developing therapies, with benefits ranging from speeding recruitment to decreasing costs.
Pharma Marketing Network
FEBRUARY 10, 2022
Innovative social media marketers from top life sciences companies discussed the secrets to their success at the Pharma Marketing Network’s 2022 Future Forecast on January 25 th. Here are the top three things to know about pharma social media trends in 2022: 1. Don’t be afraid to try new things. Social media trends change all the time, and pharma marketing organizations have to be nimble to make the most of them, according to Lauren Sacks , Director of Omnichannel Marketing at Biohaven Pharmaceu
Pharma Times
FEBRUARY 11, 2022
Rare viral haemorrhagic disease similar to Ebola surface in the East of England
pharmaphorum
FEBRUARY 10, 2022
Amazon has passed another milestone in the rollout of its healthcare business, makings it telehealth service available nationwide in the US and adding another 20 cities to its in-person services. The online retail giant first started offering the Amazon Care service to some of its own employees in 2019, expanding it to all its US workforce in 2021 and offering it to other organisations, including recently the Hilton hotel chain.
Outsourcing Pharma
FEBRUARY 7, 2022
The collaboration between the trial tech company and heathcare firm is aimed at increasing study access at MinuteClinic locations using Medableâs software.
pharmaphorum
FEBRUARY 11, 2022
Ipsen has started exclusive negotiations that could see its global consumer health business sold to fellow French pharma company Mayoly Spindler later this year. If consummated, the deal would bring in around €350 million for Ipsen , leaving the company as a specialty pharma pure-play in cancer, rare diseases and neuroscience and ending its strategy of adopting a combined prescription and over-the-counter (OTC) medicines business model.
pharmaphorum
FEBRUARY 8, 2022
Glasgow, UK (24th November, 2021) – Formedix , a leading provider of clinical trial software solutions, announces the launch of the Formedix ryze Community, to provide their customers with a location to collaborate, expand their knowledge and share information. Through a range of tools, the ryze Community will support the pharmaceutical industry to streamline and enhance clinical trial set-up and build.
pharmaphorum
FEBRUARY 10, 2022
The FDA has granted fast-track status to Bayer’s oral Factor Xia inhibitor asundexian, which is in phase 2 testing as an anticoagulant that could offer safety advantages over current drugs. Asundexian (also known as BAY2433334) will be given a speedy review by the US regulator as a secondary preventative treatment for people with ischaemic stroke, specifically those with non- cardioembolic risk factors like narrowed arteries.
pharmaphorum
FEBRUARY 8, 2022
Pfizer reckons it will make a whopping $22 billion in sales of its oral COVID-19 antiviral Paxlovid in 2022, with another $32 billion from its BioNTech-partnered coronavirus vaccine Comirnaty. The massive windfall revenues will drive its sales up towards the $100 billion mark – it’s estimating a range of $98 to $102 billion – up from $81.3 billion in 2021, which was almost twice revenues in the prior year.
pharmaphorum
FEBRUARY 7, 2022
The last three years in pharma have seen a growing awareness of and dissatisfaction with a trend that has plagued the industry for its whole life: Nondiverse and unrepresentative clinical trials, which lead to incomplete data and compounded health disparity for minority populations. It’s been more than a year since the US Food and Drug Administration released its final guidance on diversifying clinical trials in November 2020.
pharmaphorum
FEBRUARY 10, 2022
In the latest episode of the pharmaphorum podcast, editor in chief Jonah Comstock speaks with Jennifer Goldsack, CEO of the Digital Medicine Society (DiMe). Tune in to hear about the year ahead in digital health and life sciences, as well as the need for partnership and collaboration more broadly between the pharma and tech worlds. Goldsack reports on what she heard in the virtual events surrounding JP Morgan this year, and then puts some of those insights into context out of her own experience.
pharmaphorum
FEBRUARY 8, 2022
The rise in the use of decentralised clinical trial (DCTs) designs forced by COVID-19 looks set to outlast the pandemic, and digital health company Seqster has formed another partnership to tap into the shift from traditional site-based studies. The latest agreement is with contract research organisation United BioSource (UBC), which will use Seqster’s expertise in collecting and analysing data from electronic health records (EHRs), genomic studies, wearables, and other sources in remote t
pharmaphorum
FEBRUARY 8, 2022
Covid-19 has lit a fire under the medical industry, driving them to re-evaluate and incorporate digital engagement models. Now, healthcare companies have a unique opportunity to continue this momentum beyond the pandemic bubble as Healthware Group CEO Roberto Ascione tells Dr Paul Tunnah at the 2021 Frontiers Health conference in Milan. Digital health has undergone a dramatic transformation over the past few years.
pharmaphorum
FEBRUARY 8, 2022
An oral drug developed by RedHill Biopharma has reduced mortality in severe COVID-19 patients when added to therapy with corticosteroids and Gilead Science’s intravenous antiviral Veklury, setting up regulatory filings. The phase 2/3 trial also showed that opaganib – an oral sphingosine kinase-2 (SK2) inhibitor – improved survival by 70% by day 42 compared to placebo when given on top of standard care, and improved the chances of recovery at day 14 by a third, from 27.9% to 37.4%.
Expert insights. Personalized for you.
134 
Let's personalize your content